Fasolo intends to retire at the end of the year after spending close to two decades at J&J. The company picked Kristen Mulholland to succeed him, effective Oct. 1. Fasolo and Mulholland will work together during a transition period until Fasolo’s retirement becomes official.
In 2004, Fasolo joined Johnson & Johnson as worldwide VP of HR in the MedTech segment. He also served as chief talent officer before becoming chief HR officer and a member of the executive committee in 2010.
Highlights of his tenure include strengthening the company’s diversity, equity and inclusion efforts and expanding employee benefits and policies. The company said he spearheaded the increase of paid time off for leaves such as military, parental, bereavement, volunteerism and mental wellbeing.
“Peter has led J&J’s talent strategy for the past 16 years including remarkable leadership through the global pandemic and the separation of our consumer health business,” said Joaquin Duato, chair and CEO. “Throughout his career, Peter has always led with two principles in the forefront of every decision and recommendation – Our credo values and a deep responsibility to our employees. He leaves a legacy of strong leaders, deep bench strength and an inclusive, caring and patient-focused culture.”
Mulholland brings experience across the company’s Innovative Medicine and MedTech sectors. She also managed the HR business unit for Johnson & Johnson’s global corporate functions. Mulholland previously led corporate HR services, including performance and development and global total rewards.
Since joining the company in 2005, Mulholland’s stint at J&J spans HR leadership positions across multiple functions and businesses. She also played a key role in the separation of the Kenvue consumer business.
“I’m pleased to appoint Kristen to this important role where she will apply her deep business acumen, talent expertise and Credo-based approach to advance J&J’s culture and operating model,”Duato said. “I’m confident her breadth of experience and strong leadership will ensure Johnson & Johnson’s human capital strategy is poised to deliver the innovative future-ready talent and culture needed to advance healthcare solutions for patients worldwide.”
